Cell Biotech Proves Effect of Improving MCI(Mild Cognitive Impairment) with CBT-LR5

Through clinical trials using the patented probiotics "CBT-LR5 (KCTC 12202BP)," Cell Biotech proved the possibility of improving mild cognitive impairment (MCI) in the elderly and presented a new scientific basis for the "Gut-Brain Axis" theory that intestinal health can affect brain health. The results of the study are published in the prestigious SCI-level international journal 'Nutrients (IF: 4.8)' in the field of nutrition and announced the possibility of developing alternative treatments for MCI, which corresponds to the pre-dementia stage, at home and abroad.

MCI is an intermediate stage between dementia and normal aging, and many of them may progress to Alzheimer's disease. However, so far, treatment has been mainly medication, which has been accompanied by cost burden and side effect issues. Cell Biotech has developed MH-Pro, a combination of CBT-LR5 strain and skim milk powder, and conducted clinical trials with the aim of improving awareness based on functional probiotics with low side effects and high safety.

This clinical trial was conducted in collaboration with Chonbuk National University Hospital, and was conducted in a randomized and double-blind manner for 12 weeks in 20 suspected MCI subjects with an average age of 68.9. The overall cognitive function improvement effect of 'CBT-LR5' was analyzed through comparative analysis between intake dose groups of the same product.

As a result, the total score of the Korean-style Montreal Cognitive Assessment (MoCA-K) increased by 18.9% (p=0.004) compared to before ingestion, confirming a significant improvement in cognitive function. In particular, the score improvement was evident in multiple cognitive areas such as ▲ Spatial Recognition (Orientation), ▲ Delayed Recall, and ▲ Naming. No adverse reactions were observed in all participants, and the high adherence to the medication was over 97%, proving both safety and practicality.

As a result of intestinal microbiome analysis, an increase in beneficial bacteria was observed after ingesting MH-Pro, which showed a close correlation with the MoCA-K score, confirming that the intestinal environment could affect cognitive function. This study suggests the possibility that the probiotics-based "gut-brain axis" regulation strategy could be a practical approach to improving cognitive function in the elderly.

"This paper proved that its strain development capabilities, which have been accumulated for 30 years, can be a practical solution to the public health issue of improving the cognition of the elderly," a Cell Biotech official said. "CBT-LR5 is a next-generation cognitive health functional material that can be used for pre-dementia management in the future, and has a very high growth potential."